OUTER HOUSE, COURT OF SESSION
[2007] CSOH 211
|
A613/07
|
OPINION OF LORD EMSLIE
in the cause
ONYVAX LIMITED
Pursuers;
against
ENDPOINT RESEARCH (UK)
LIMITED
Defenders:
ннннннннннннннннн________________
|
Pursuers: Sandison;
Brodies LLP
Defenders: Hayhow;
Thorntons Law LLP
28 December 2007
[1] In
this motion for an interim order
under section 47(2) of the Court of Session Act 1988, the pursuers seek
delivery of a Trial Master File ("TMF") which is said to contain composite
details of certain clinical trial work undertaken by the defenders on their
behalf in connection with the development of a new cancer vaccine. The TMF is apparently the last outstanding
document to be handed over by the defenders following the recent termination of
their engagement and the transfer of all ongoing trial work to others. Having originally contemplated an amicable
handover of this document, the defenders now decline to co-operate, and instead
assert a common law lien on account of the pursuers' non-payment of work
invoices to the tune of just over г147,000.
On the basis of an arbitration clause in the parties' contract (the
Master Service Agreement, or "MSA"), the defenders also maintain that this
court has no jurisdiction to entertain the present application. The pursuers' position, on the other hand, is
that the defenders have impliedly abandoned their right to arbitrate by raising
a Sheriff Court action for
payment of the outstanding invoices.
More importantly, they point out that any arbitration would be subject
to the UNCITRAL model law in terms of section 66 of the Law Reform
(Miscellaneous Provisions) (Scotland) Act 1990, which preserves the
jurisdiction of the court relative to interim
orders unless and until the same matter is determined by the arbiter.
[2] The
parties are in agreement that the proper approach to an application for an interim order under section 47(2)
is that affirmed by an Extra Division in Scottish
Power Generation Ltd v British Energy
Generation (UK) Ltd 2002 SC 517. Paragraph [26] of the opinion of the court
is in the following terms:
"From these
authorities we derive the following principles which are relevant to a case of
the present kind. First, the Lord
Ordinary has to identify the issues in the action, including the legal basis of
the claims with which he is dealing.
Secondly, he has to consider whether the party seeking the order has
demonstrated a prima facie case that
an obligation exists, and that there is a continuing or threatened breach of
that obligation which the order will address.
Thirdly, he has to avoid significantly innovating on the parties'
contractual rights and obligations.
Fourthly, he has to consider whether the balance of convenience is such
as to justify the making of the interim
order, bearing in mind the nature and degree of the harm likely to be suffered
on either side by the grant or refusal of the interim order, and the relative strength of the cases put forward
by each party."
The parties are, however, in
dispute as to whether these requirements for an interim order have been made out in the present case.
[3] Before
me the pursuers' claim was pointedly not
founded on any express handover obligation in the MSA, since the defenders
might then admittedly withhold performance of such obligation while their
invoices remained unpaid. On the
contrary, the pursuers relied on their undisputed right of ownership of the
TMF, and on the concomitant right to recover its possession from the defenders
on demand. According to counsel this was
a sufficient prima facie case for the
purposes of section 47(2), especially when coupled with the invalidity of
the alleged lien on which the defenders principally sought to found. In particular, it was said, no valid lien
could be asserted here because that would be inconsistent with the express
terms of the parties' agreement and of certain documents incorporated
therein. Moreover, since lien was an
equitable remedy, the court could not sanction it where the equities were in
the pursuers' favour.
[4] On
similar grounds, the balance of convenience strongly favoured the
pursuers. The TMF contained essential
details, unavailable to the pursuers, of the precise performance of the trials
relative to individual patients in many countries across the world. The pursuers admittedly knew how these trials
should, by design, have been carried out, but in the absence of actual data
regarding dosages, dates and the like they could not be sure that all necessary
information would be available to deal safely and effectively with any "adverse
event" which might arise. This posed a
serious potential risk to patients where neither the pursuers nor the new trial
operator would be able to assess any link to prior trial activity, or indeed to
determine the appropriate remedial treatment to be adopted. The new trial operator had to date proceeded
on certain assumptions, but this state of affairs was highly unsatisfactory and
represented a breach of the principles enshrined in the Declaration of Helsinki
(1964) and other documents incorporated into the MSA, whereby patient safety
was a paramount consideration. As stated
in paragraph A5 of the Declaration, "... considerations related to the
well-being of the human subject should take precedence over the interests of
science and society". As a result of the
defenders' failure to deliver the TMF, the pursuers were also placed in
continuing breach of their obligation to keep and maintain a TMF under
Regulation 31A(1) and (2) of the Clinical Trials Regulations 2004.
[5] In
these circumstances, the defenders' withholding of the TMF for purely
commercial reasons was irresponsible and immoral as well as unlawful, and an interim order for delivery was thus
amply justified. Although the defenders
clearly regarded the contents of the TMF as sufficiently valuable to warrant
retention, they were unable or unwilling to identify the nature of that
value. This seriously undermined their
claim to have disclosed all relevant patient information to the pursuers
already, and tended to support the pursuers' position on the balance of
convenience. The defenders' private
commercial interests could not be allowed to override the health and safety of
patients, especially where an interim
order for delivery would in no way innovate on the parties' contractual rights
and obligations. Paragraphs 8.1 and
12.3 of the MSA were in the following terms:
"8.1 All Intellectual Property
and work product generated in any form or media in the course of the
performance of the Services by Endpoint ...
is the sole and exclusive property of Onyvax
and shall be remitted by Endpoint to
Onyvax no later than the termination
date of this Agreement.
12.3 Upon request of Onyvax and/or at the end of the work
covered by this Agreement, Endpoint
will promptly return all documents and information made available to Endpoint and created by Endpoint during the course of the work
covered by this Agreement."
Nor could it be said that an interim order at this stage would be
inappropriate as exhausting the pursuers' claims in this action. On the contrary, an interim order made on prima
facie grounds would not resolve the declarator sought in the first
conclusion, nor would it affect the substantial pecuniary claims which had
recently been added by amendment.
[6] In
all the circumstances, counsel submitted that the requirements laid down in the
Scottish Power case had been
satisfied, and that they were entitled to the interim order which they sought.
If so required by the court, they might be prepared to consign up to
г120,000 in return, but their primary position remained that the motion was
justified and should be granted without qualification. As between the parties it was the defenders
and not the pursuers who were in financial difficulty, and where the pursuers
were solvent the defenders could not be said to require any security for their
pecuniary claims.
[7] In
response, counsel for the defenders agreed that the requirements for an interim order under section 47(2)
of the 1988 Act were those set out in the Scottish
Power decision. He also accepted
that, in principle, the only answer to a claim based on ownership would be a
special lien, and that such a lien could not be asserted where it was
inconsistent with contractual obligations, or indeed if the court intervened on
equitable grounds. That said, however,
he maintained that there were several distinct grounds on which the pursuers'
motion was ill-founded and should be refused.
[8] First, the defenders were well entitled
to assert a lien over the TMF while their invoices totalling over г147,000
remained unpaid. As explained in the Stair Memorial Encyclopaedia, vol.20 at
para.75, such a lien rested on principles of mutuality and would clearly cover
the TMF which was in part provided by the pursuers and in part generated by the
defenders in the course of their work.
Clauses 8.1 and 12.3 of the MSA were not inconsistent with the
existence of the lien, and clause 10.3 plainly contemplated such a remedy
being open to the defenders where (as here) the pursuers had defaulted on the
payment of sums contractually due. There
was thus no obligation on the defenders to return the TMF until the parties'
contractual disputes had been resolved.
In this context the Declaration of Helsinki and other incorporated
documents were irrelevant, since they were aspirational in nature and sought to
regulate the conduct of clinical trials rather than the resolution of
subsequent disputes. Moreover, retention
of the TMF did not place the pursuers in breach of Regulation 31A of the
2004 Regulations. On one view,
compliance was achieved by the defenders' retention of the document on the
pursuers' behalf, but in any event the pursuers were already in default by
having failed to keep a full copy of the TMF for themselves.
[9] Over
and above that, there was no equitable basis on which the court should
interfere to prevent assertion of the defenders' lien. The alleged risk to patient safety was not
accepted. No such risk had materialised
since the parties came to court in September, and in any event the pursuers already
had all relevant information, including patient data, that they could
reasonably require. The pursuers' offer
to mediate was admittedly a factor which could be taken into account, but it
was important to remember that arbitration had been agreed by the parties as
the appropriate method of settling any dispute.
The defenders had made various efforts in that direction, although as
yet no sist of the Sheriff Court
proceedings had occurred. As regards the
parties' respective finances, the pursuers remained unwilling to consign
anything in return for an interim
order, and without consignation of the full sum in dispute no such order would
be appropriate. In all these circumstances,
neither contract nor equity could properly deprive the defenders of their
lien.
[10] Second, the effect of
the parties' arbitration clause was to oust the jurisdiction of all courts for
present purposes. On the authorities,
the raising of proceedings in the Sheriff Court would not per se indicate abandonment of the right to arbitrate, and did not
do so here. In this context, reference
was made to D & J McDougall Ltd v
Argyll & Bute District Council
1987 S.L.T. 7; Presslie v Cochran McGregor
Group Ltd 1996 S.L.T. 988; Wylie v Corrigan 1999 S.L.T. 739; Macphail, Sheriff Court Practice, 3rd
ed., para.2.99; and Davidson, Arbitration, para.7.19.
As such authorities confirmed, court proceedings might legitimately be
raised for protective purposes without in any way affecting a party's right to
go to arbitration in due course. Moreover, so far as the UNCITRAL model law was
concerned, no interim order should be
granted here where an arbitration was in prospect and the same issue could be
brought before the arbiter.
[11] Third, the balance of
convenience and the wider equities favoured the defenders. The pursuers already had all of the
information which they could legitimately require for the purposes of patient
safety, and could readily reconstitute a TMF of their own from such materials
as they held. Esto the pursuers were in breach of Regulation 31A of the 2004
Regulations, that breach pre-dated the present dispute. More importantly, the defenders had
repeatedly undertaken to make the TMF available for audit and regulatory purposes,
so that any real prejudice to the pursuers would be avoided. Such access had already been offered in
December 2006 while the contract was in operation. Moreover, the grant of an unqualified interim order would deprive the
defenders of legitimate security for sizeable financial claims.
[12] For all of these reasons, counsel submitted that this was not
an appropriate case for an interim
order under section 47(2) of the 1988 Act.
[13] Having taken time to consider the parties' competing
contentions, I have reached the conclusion that a conditional interim order should be granted in the
circumstances of this case. Such an
order would remove an unnecessary complication from the scope of the parties'
dispute; it would remove any possible
risk to patient safety in the shorter and longer term; and it would leave the parties free to
resolve their remaining differences along ordinary commercial lines. By contrast, refusal of the motion would in
my view risk continuing endangerment of the health and safety of third
parties; it would perpetuate an area of
disagreement where entrenched and unreasonable attitudes are to my mind already
beginning to be evident; and it would
give the parties no assistance towards ultimate resolution of the real dispute
between them. Refusal of the motion
would, I believe, be in nobody's interests at the present time.
[14] Both parties acknowledge that the issue between them is as
between the pursuers' right of ownership, on the one hand, and the defenders'
asserted lien on the other. Prima facie I consider that the pursuers
are entitled to assert that right of ownership, and to obtain delivery of the
TMF at this stage, unless the defenders can identify some legal justification
for their refusal to comply. But for the
existence of the parties' contractual arrangements, in the form of the MSA and
associated documents, it would in my view have been difficult to find much to
say in favour of the defenders' position.
According to the latest accounts produced, they are a company with a
serious balance sheet deficit. They have
ceased to trade in the United Kingdom,
maintaining only a formal registered office here, and they may now have no
senior personnel who remain directly amenable to the jurisdiction of this
court. Furthermore, the TMF has for some
months been held in Toronto, Canada,
albeit apparently in a purpose-built, secure location. In the course of the hearing, counsel for the
defenders was unable to identify any value which the TMF might represent to
them, other than as a lever or bargaining counter in connection with their
financial claim. To date they have
refused the pursuers' offer to mediate, or otherwise to enter into discussions
on outstanding issues, and although pleading the arbitration clause they have
as yet taken no effective steps in that direction. Indeed they have raised a Sheriff Court
action for payment of the outstanding invoices, and although I do not accept
that abandonment of the right to arbitrate can yet be inferred it is clear that
further pursuit of that action might soon have that effect. No doubt the defenders have given certain
undertakings with regard to production of the TMF to meet audit and regulatory requirements,
but at the same time they flatly refuse to make it available for any other
purpose. If, as the pursuers contend,
the absence of materials within the TMF presents a potential risk to the health
and safety of patients, then the defenders may be seen as willing to ignore
that risk for their own commercial advantage.
[15] As against that, the pursuers' position is not self-evidently
beyond reproach either. Past invoices to
the value of more than г147,000 remain unpaid;
the pursuers seem unwilling to acknowledge the ambit of the arbitration
clause in the MSA where, to my mind, it covers broadly the same ground as
clause 24 which prorogates the jurisdiction of the Scottish courts; and they assert a material risk to the health
and safety of patients without explicit identification of the crucial materials
which the TMF is said to contain. That
said, however, I cannot ignore the fact that this latter assertion was made and
repeated by responsible counsel, nor can I in all conscience ignore the
possibility (albeit disputed by the defenders) that the assertion may be
correct. In the course of the debate
before me, counsel for the defenders very fairly accepted that the disputed
health risk to patients was a factor which would have to be taken into account
for present purposes.
[16] In my opinion the parties' contract is of great significance
here. In general terms, I think that its
existence materially qualifies the right of ownership in the TMF which the
pursuers seek to assert. In particular,
it spells out the basis on which materials owned by the pursuers may
legitimately be held by the defenders, at least during the progress of the
trials and/or the subsistence of the parties' arrangements. It is thus essentially to the contract that
one must look in order to ascertain whether, in present circumstances, the
pursuers are in a position to demand the immediate return of their property
including the TMF. On the face of the
MSA, it seems to me that the pursuers have an express entitlement to demand the
return of these materials.
Paragraphs 8.1 and 12.3 in particular bear to confer such rights by
reference to either (i) the date of a demand or (ii) the cessation of
work or (iii) the termination of the Agreement. On the other hand, the lien which the
defenders assert is founded on the principle of mutuality of obligations, and
in that respect is similar to the contractual right of retention which the
defenders might have asserted in other circumstances. The key difference here, however, is that
whereas retention would have been a legal right, the defenders' lien is in the
nature of an equitable claim subject to the scrutiny and control of the
court.
[17] In my opinion the lien which the defenders assert is not
necessarily inconsistent with the express terms of the MSA and associated
documents. These contractual materials
contain no clause or qualification to the effect that no lien may be asserted,
and I can see no obvious reason why a lien should be any less valid where
contractual redelivery dates are specified than when they are not. For instance, a lien asserted while the MSA
remained in force would not in my view simply fly off on its termination. Similarly I am unable to accept that the
incorporated affirmation of patient safety as a guiding principle can properly
be read as an implied bar to the assertion of a special lien in any
circumstances.
[18] Against that background, the basis for my decision comes to be
the equitable nature of the special lien which the defenders assert. In my opinion it would be unconscionable to
allow that lien to be asserted on an unqualified basis, having regard in
particular to (i) the risk to the health and safety of patients which,
according to the pursuers, flows from the unavailability of the TMF; (ii) the fact that the TMF is apparently
being held by the defenders in Toronto, and outwith the prorogated jurisdiction
of this court; (iii) the questions
regarding the defenders' financial viability which appear to be raised by their
own recent accounts; (iv) the
defenders' refusal to mediate or otherwise to discuss the parties' current
disagreements; and (v) the apparent
lack of value of the TMF to the defenders, other than as a lever or bargaining
counter in relation to their outstanding financial claim.
[19] On the other hand, I do not consider that the pursuers, for
their part, can legitimately claim delivery of the TMF on unqualified terms
either. Their problem is that they now
refuse to pay past invoices totalling over г147,000, and in that situation
unqualified delivery would in my view only be appropriate if it could be said
that the defenders had no potentially valid right of lien to assert at
all. For the reasons set out above, it
seems to me that the defenders do have such a right, although subject to the
equitable scrutiny and control of the court, and I therefore find it impossible
to accede to the pursuers' primary motion for unqualified interim delivery of the TMF.
[20] Taking all of these considerations into account, I have come to
the view that an interim order should
be granted here, but that it should be made conditional on the pursuers
consigning the whole of the disputed sum of г147,267.70 in court pending
determination or settlement of the defenders' claim for payment of their
outstanding invoices. Along similar
lines, the lifting of a lien subject to consignation was ordered by the court
in Garscadden v Ardrossan Dry Dock & Shipbuilding Co Ltd 1910 S.C. 178, and it
is also significant that during the debate before me the pursuers reluctantly
expressed willingness to consign a substantial sum in court if required, and
the defenders in turn indicated that consignation of the disputed sum would
represent an appropriate solution.
[21] On the whole matter, I am satisfied that the requirements for
an interim order under
section 47(2) of the 1988 Act have been made out in this case. The pursuers' prima facie entitlement to receive possession of the TMF which they
own is beyond dispute; the express
clauses of the contract confirm that entitlement; and in my judgment the pursuers have also
made out a prima facie entitlement to
have the defenders' lien cut down on equitable grounds. Furthermore the UNCITRAL model law permits interim orders to be obtained from the
court notwithstanding the existence of a contractual arbitration clause. If anything innovates on the parties' express
contract, it is the equitable lien asserted by the defenders, and for the
reasons already given I do not consider that that can receive unqualified
effect. The equities, and the balance of
convenience, clearly favour the release of the TMF into the pursuers' possession
now, but only upon consignation of the disputed sum of г147,267.70 in the hands
of the court. Subject to that condition,
I now grant the pursuers' motion.